Antibody drug conjugates are the new drug class which exploits the specificity of monoclonal antibodies to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload.
Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights:
- Global & Regional Combination Cancer Immunotherapy Market Insight Till 2028
- Combination Cancer Immunotherapy Market By Different Cancers
- Patent, Price & Dosage Analysis On Approved Combination Drugs
- Global & Regional Sales Insights On Approved Combination Drugs Till 2028
- Insight on 600 Combination Cancer Immunotherapy Drugs In Clinical Trials
- Insight on 45 Combination Cancer Immunotherapy Drugs Commercially Approved In Market
- Clinical Trials & Patent Insight By Company, Country, Indication & Phase
Download Report:
https://www.kuickresearch.com/report-combination-cancer-therapy-market
Antibody drug conjugates are the new drug class which exploits the specificity of monoclonal antibodies to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. This drug class presents a unique opportunity to deliver drugs to tumor cells while minimizing toxicity to normal tissue, achieving wider therapeutic windows and enhanced pharmacokinetic and pharmacodynamic properties. However, the effectiveness of antibody drug conjugates depend on several factors including tumor expression levels of target antigen as well as ability of tumor cells to internalize and cleave the conjugated drug and undergo apoptosis in response. Recently, it has been shown that this activity can be further enhanced by concurrent administration of other cancer therapies.
Recently in 2022, US FDA has granted approval to Adcetris (brentuximab vedotin) in combination with chemotherapy for the management of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma. The approval is based on the promising results from ECHELON-1 clinical trial which evaluated and compared the efficacy of Adcetris plus AVD (Adriamycin, vinblastine and dacarbazine) to ABVD (Adriamycin, bleomycin, vinblastine and dacarbazine) chemotherapy. The data from the trial suggested that Adcetris AVD significantly reduce the risk of relapse, improve survival and avoids bleomycin lung toxicity.
Apart from this, European Marketing Authorization has also approved Polivy (polatuzumab vedotin) in combination with Rituximab plus cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the management of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL). The approval is based on POLARIX study (GO39942), which demonstrated that the combination significantly enhanced the progression free survival in comparison to standard of care rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). In addition, there were no treatment related adverse events and the combination showed comparable safety profile. The entrance of antibody drug conjugates in combinational therapy is expected to revolutionize the overall paradigm of cancer therapy.
The global combinational immunotherapy market is highly competitive and consists of several key players which actively invest in research and development activities. Till date, there are more than 3000 ongoing clinical trials which are evaluating the role of immunotherapy as combinational therapy. In April 2022, Sotio Biotech announced that it has dosed the first patient in its phase-I/II CLAUDIO-01 trial of SOT102 in patients with gastric and pancreatic cancer. The phase-I/II trial is open-label, multicenter clinical trial to access the safety and preliminary efficacy of SOT102 in monotherapy and in combination with established standard of care therapies.
The key players in the market have also adopted strategic alliances such as collaboration, partnership, or joint ventures to maintain their position in the global market. For instance, in January 2022, BioAtla entered into clinical collaboration with Bristol Myers Squibb to evaluate BioAtla two lead CAB-ADC candidates, BA3011 and BA3021, in combination with Bristol Myers Squibb’s anti-PD-1 therapy, Opdivo. Under the terms of agreement, BioAtla and Bristol Myers Squibb will collaborate on clinical trials of separate combinational therapies using two of BioAtla’s Conditionally Active Biologic Antibody Drug Conjugates, BA3011 and BA3021, each in combination with Opdvio. BioAtla will serve as the study sponsor and will be responsible for costs associated with the trial execution. Bristol Myers Squibb will provide Opdivo clinical drug supply for the study. The other key players in market include Roche, Novartis, GlaxoSmithKline, Bayer, Gilead Sciences, Merck, and other.
Contact:
Neeraj Chawla
Kuick research
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com